This new approval provides clinicians with the option to prescribe VIMPAT to their pediatric patients either as an oral solution or a convenient tablet. 1 This allows for flexible administration ...

ATLANTA, June 29, 2010 /EurekAlert!/ — New long term data showed that Vimpat® (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment ...

Topline results of a phase 3 trial support a supplemental New Drug Application for lacosamide (Vimpat, UCB) as monotherapy for patients with partial-onset seizures, the company has announced.

October 31, 2008 — The US Food and Drug Administration (FDA) has approved lacosamide as add-on therapy for adults with partial-onset seizures, and 2 new dosage strengths of a compound combining ...

- Results from VIMPAT® (lacosamide) monotherapy study supporting this filing to be presented at AES 2013 "UCB has a strong heritage in epilepsy. The US filing for lacosamide in monotherapy is another ...

The FDA also approved Vimpat Injection for use in pediatric patients 4 years of age and older. The Food and Drug Administration (FDA) has approved Vimpat ® (lacosamide; UCB) as adjunctive therapy in ...

More patients with epilepsy have a treatment option following the Food and Drug Administration's approval of an indication expansion for UCB's Vimpat (lacosamide) CV. The agency approved Vimpat as ...

BRUSSELS, BELGIUM--(Marketwire - July 29, 2008) - 6 pm CEST - press release, regulated information: UCB announced today that it received a not-approvable letter from the U.S. Food and Drug ...

UCB today announced new findings from analyses of pooled Vimpat(r) (lacosamide) clinical trial data, demonstrating that the new antiepileptic drug (AED) starts working during the first week of ...

Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy - Vimpat(R) demonstrated greater seizure ...

DUBLIN--(BUSINESS WIRE)--The "Epilepsy Drugs Market by Country (US, UK, France, etc), Drugs (Vimpat, Keppra, Sabril, Onfi, etc), Treatment Drugs Generation (First ...

New long term data showed that Vimpat® (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures ...